Longitudinal PET/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis.

Autor: Lands, Ronald, Martin, Emily B., Powell, Dustin, Stuckey, Alan, Whittle, Bryan, Guthrie, Spencer, Raj, Renju, Kennel, Stephen J., Wall, Jonathan S.
Předmět:
Zdroj: Amyloid; Jun2024, Vol. 31 Issue 2, p148-149, 2p
Abstrakt: This article discusses the use of a novel imaging technique called positron emission/x-ray computed tomographic (PET/CT) imaging with iodine-124 (124I-evuzamitide) to monitor the response to therapy in a patient with AL amyloidosis. The study involved a 70-year-old male who was treated with daratumumab immunotherapy. The PET/CT imaging revealed a decrease in radiotracer uptake in the liver, spleen, and bone marrow, indicating a reduction in amyloid load. However, there was an increase in radiotracer accumulation in the kidney. The findings suggest that organ-specific responses to therapy may occur independently and at different rates. This study highlights the potential of PET/CT imaging with 124I-evuzamitide in diagnosing amyloidosis and monitoring changes in organ-specific amyloid load. [Extracted from the article]
Databáze: Complementary Index